{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T20:11:53Z","timestamp":1792872713649,"version":"4.5.0"},"reference-count":70,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:00:00Z","timestamp":1726704000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["CMML Special Initiative: Synergistic Team Award"],"award-info":[{"award-number":["CMML Special Initiative: Synergistic Team Award"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017570","name":"Commonwealth Serum Laboratories","doi-asserted-by":"publisher","award":["2020 Centenary Fellowship"],"award-info":[{"award-number":["2020 Centenary Fellowship"]}],"id":[{"id":"10.13039\/501100017570","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Medical Research Future Fund","award":["1201012, 2024427, 2008972"],"award-info":[{"award-number":["1201012, 2024427, 2008972"]}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2023\/GNT2029809"],"award-info":[{"award-number":["2023\/GNT2029809"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["LLS 6619-21, LLS 6650-23"],"award-info":[{"award-number":["LLS 6619-21, LLS 6650-23"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021839","name":"Snowdome Foundation","doi-asserted-by":"publisher","award":["LLS 6619-21, LLS 6650-23"],"award-info":[{"award-number":["LLS 6619-21, LLS 6650-23"]}],"id":[{"id":"10.13039\/501100021839","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000926","name":"Leukaemia Foundation","doi-asserted-by":"publisher","award":["LLS 6619-21, LLS 6650-23"],"award-info":[{"award-number":["LLS 6619-21, LLS 6650-23"]}],"id":[{"id":"10.13039\/501100000926","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Chronic myelomonocytic leukemia (CMML) is a rare blood cancer of older adults (3 in every 1,000,000 persons) characterized by poor survival and lacking effective mutation-specific therapy. Mutations in the ubiquitin ligase Cbl occur frequently in CMML and share biological and molecular features with a clonal disease occurring in children, juvenile myelomonocytic leukemia (JMML). Here we analyzed the clinical presentations, molecular features and immunophenotype of CMML patients with <jats:italic>CBL<\/jats:italic> mutations enrolled in a prospective Phase II clinical trial stratified according to molecular markers. Clinically, <jats:italic>CBL<\/jats:italic> mutations were associated with increased bone marrow blasts at diagnosis, leukocytosis and splenomegaly, similar to patients harboring <jats:italic>NRAS<\/jats:italic> or <jats:italic>KRAS<\/jats:italic> mutations. Interestingly, 64% of patients presented with more than one <jats:italic>CBL<\/jats:italic> variant implying a complex subclonal architecture, often with co-occurrence of <jats:italic>TET2<\/jats:italic> mutations. We found <jats:italic>CBL<\/jats:italic> mutations in CMML frequently clustered in the RING domain in contrast to JMML, where mutations frequently involve the linker helix region (<jats:italic>P<\/jats:italic>&lt;0.0001). According to our comparative alignment of available X-ray structures, mutations in the linker helix region such as Y371E give rise to conformational differences that could be exploited by targeted therapy approaches. Furthermore, we noted an increased percentage of CMML CD34<jats:sup>+<\/jats:sup> stem and progenitor cells expressing CD116 and CD131 in all <jats:italic>CBL<\/jats:italic> mutant cases and increased CD116 receptor density compared to healthy controls, similar to CMML overall. In summary, our data demonstrate that <jats:italic>CBL<\/jats:italic> mutations are associated with distinct molecular and clinical features in CMML and are potentially targetable with CD116-directed immunotherapy.<\/jats:p>","DOI":"10.1371\/journal.pone.0310641","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T17:40:42Z","timestamp":1726767642000},"page":"e0310641","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":7,"title":["CBL mutations in chronic myelomonocytic leukemia often occur in the RING domain with multiple subclones per patient: Implications for targeting"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4606-7588","authenticated-orcid":true,"given":"Kelly","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5844-7644","authenticated-orcid":true,"given":"Winnie L.","family":"Kan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8630-0121","authenticated-orcid":true,"given":"Pramod C.","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Kutyna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel F.","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5290-9206","authenticated-orcid":true,"given":"Timothy","family":"Hercus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Lane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5773-103X","authenticated-orcid":true,"given":"Chun Yew","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes","family":"Yong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devendra","family":"Hiwase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0837-1231","authenticated-orcid":true,"given":"Daniel","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,9,19]]},"reference":[{"issue":"1","key":"pone.0310641.ref001","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2008-01-134858","article-title":"Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001\u20132004, using data from the NAACCR and SEER programs","volume":"112","author":"DE Rollison","year":"2008","journal-title":"Blood"},{"issue":"7","key":"pone.0310641.ref002","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1080\/10428194.2016.1258700","article-title":"Incidence and survival outcomes of chronic myelomonocytic leukemia in the United States","volume":"58","author":"GS Guru Murthy","year":"2017","journal-title":"Leukemia & Lymphoma"},{"issue":"23","key":"pone.0310641.ref003","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1182\/blood-2015-01-620781","article-title":"Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia","volume":"125","author":"D Selimoglu-Buet","year":"2015","journal-title":"Blood"},{"issue":"13","key":"pone.0310641.ref004","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1182\/blood-2016-12-753210","article-title":"Monocyte subset analysis accurately distinguishes CMML from MDS and is associated with a favorable MDS prognosis","volume":"129","author":"C Talati","year":"2017","journal-title":"Blood"},{"issue":"16","key":"pone.0310641.ref005","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1182\/blood-2013-03-491399","article-title":"Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia","volume":"122","author":"K Takahashi","year":"2013","journal-title":"Blood"},{"issue":"1","key":"pone.0310641.ref006","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/ajh.24939","article-title":"Therapy related-chronic myelomonocytic leukemia (CMML): Molecular, cytogenetic, and clinical distinctions from de novo CMML","volume":"93","author":"MM Patnaik","year":"2018","journal-title":"Am J Hematol"},{"issue":"7","key":"pone.0310641.ref007","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/ajh.23415","article-title":"Sweet\u2019s syndrome in chronic myelomonocytic leukemia","volume":"88","author":"M Saffie","year":"2013","journal-title":"American Journal of Hematology"},{"issue":"2","key":"pone.0310641.ref008","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1159\/000365877","article-title":"A close association of autoimmune-mediated processes and autoimmune disorders with chronic myelomonocytic leukemia: observation from a single institution","volume":"133","author":"D Peker","year":"2015","journal-title":"Acta Haematol"},{"key":"pone.0310641.ref009","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.leukres.2016.05.013","article-title":"Autoimmune and inflammatory diseases associated with chronic myelomonocytic leukemia: A series of 26 cases and literature review","volume":"47","author":"E Grignano","year":"2016","journal-title":"Leuk Res"},{"issue":"6","key":"pone.0310641.ref010","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1080\/10428194.2016.1243681","article-title":"Spectrum of autoimmune diseases and systemic inflammatory syndromes in patients with chronic myelomonocytic leukemia","volume":"58","author":"MF Zahid","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"pone.0310641.ref011","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood.V99.3.840","article-title":"Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients","volume":"99","author":"F Onida","year":"2002","journal-title":"Blood"},{"issue":"3","key":"pone.0310641.ref012","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3324\/haematol.2010.030957","article-title":"Cytogenetic risk stratification in chronic myelomonocytic leukemia","volume":"96","author":"E Such","year":"2011","journal-title":"Haematologica"},{"issue":"5","key":"pone.0310641.ref013","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/leu.2011.10","article-title":"Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80% of patients with TET2 and EZH2 being of high prognostic relevance","volume":"25","author":"V Grossmann","year":"2011","journal-title":"Leukemia"},{"issue":"2","key":"pone.0310641.ref014","doi-asserted-by":"crossref","first-page":"e393","DOI":"10.1038\/bcj.2016.5","article-title":"Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia","volume":"6","author":"MM Patnaik","year":"2016","journal-title":"Blood Cancer J"},{"issue":"19","key":"pone.0310641.ref015","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1200\/JCO.2012.47.3314","article-title":"Prognostic score including gene mutations in chronic myelomonocytic leukemia","volume":"31","author":"R Itzykson","year":"2013","journal-title":"J Clin Oncol"},{"key":"pone.0310641.ref016","doi-asserted-by":"crossref","first-page":"10767","DOI":"10.1038\/ncomms10767","article-title":"Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents","volume":"7","author":"J Merlevede","year":"2016","journal-title":"Nat Commun"},{"issue":"12","key":"pone.0310641.ref017","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1038\/leu.2017.164","article-title":"Genomic determinants of chronic myelomonocytic leukemia","volume":"31","author":"BJ Patel","year":"2017","journal-title":"Leukemia"},{"issue":"11","key":"pone.0310641.ref018","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1038\/ng.3400","article-title":"The genomic landscape of juvenile myelomonocytic leukemia","volume":"47","author":"E Stieglitz","year":"2015","journal-title":"Nature genetics"},{"issue":"11","key":"pone.0310641.ref019","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1038\/ng.3420","article-title":"Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network","volume":"47","author":"A Caye","year":"2015","journal-title":"Nature genetics"},{"issue":"1","key":"pone.0310641.ref020","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/s41467-017-02177-w","article-title":"RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia","volume":"8","author":"DB Lipka","year":"2017","journal-title":"Nat Commun"},{"issue":"14","key":"pone.0310641.ref021","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1182\/blood-2017-07-798157","article-title":"Integrated molecular profiling of juvenile myelomonocytic leukemia","volume":"131","author":"N Murakami","year":"2018","journal-title":"Blood"},{"issue":"2","key":"pone.0310641.ref022","doi-asserted-by":"crossref","first-page":"101171","DOI":"10.1016\/j.beha.2020.101171","article-title":"Juvenile myelomonocytic leukemia \u2010 A bona fide RASopathy syndrome","volume":"33","author":"T Lasho","year":"2020","journal-title":"Best Pract Res Clin Haematol"},{"issue":"9","key":"pone.0310641.ref023","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1182\/blood-2009-01-198416","article-title":"Mutations in CBL occur frequently in juvenile myelomonocytic leukemia","volume":"114","author":"ML Loh","year":"2009","journal-title":"Blood"},{"issue":"10","key":"pone.0310641.ref024","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0301-472X(02)00903-7","article-title":"Chronic myelomonocytic leukemia requires granulocyte-macrophage colony-stimulating factor for growth in vitro and in vivo","volume":"30","author":"HS Ramshaw","year":"2002","journal-title":"Exp Hematol"},{"issue":"25","key":"pone.0310641.ref025","doi-asserted-by":"crossref","first-page":"5068","DOI":"10.1182\/blood-2012-10-460170","article-title":"GM-CSF\u2013dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia","volume":"121","author":"E Padron","year":"2013","journal-title":"Blood"},{"issue":"1","key":"pone.0310641.ref026","doi-asserted-by":"crossref","first-page":"178","DOI":"10.3324\/haematol.2020.270595","article-title":"Molecular and phenotypic diversity of CBL-mutated juvenile myelomonocytic leukemia","volume":"107","author":"A Hecht","year":"2022","journal-title":"Haematologica"},{"issue":"6801","key":"pone.0310641.ref027","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/35025089","article-title":"CAP defines a second signalling pathway required for insulin-stimulated glucose transport","volume":"407","author":"CA Baumann","year":"2000","journal-title":"Nature"},{"issue":"1","key":"pone.0310641.ref028","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1182\/blood.V91.1.46","article-title":"c-Cbl is tyrosine-phosphorylated by interleukin-4 and enhances mitogenic and survival signals of interleukin-4 receptor by linking with the phosphatidylinositol 3\u2019-kinase pathway","volume":"91","author":"H Ueno","year":"1998","journal-title":"Blood"},{"issue":"1","key":"pone.0310641.ref029","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/sj.onc.1203254","article-title":"Involvement of Shc and Cbl-PI 3-kinase in Lyn-dependent proliferative signaling pathways for G-CSF","volume":"19","author":"A Grishin","year":"2000","journal-title":"Oncogene"},{"issue":"35","key":"pone.0310641.ref030","doi-asserted-by":"crossref","first-page":"4058","DOI":"10.1038\/sj.onc.1203750","article-title":"The proto-oncogene c-Cbl is a positive regulator of Met-induced MAP kinase activation: a role for the adaptor protein Crk","volume":"19","author":"M Garcia-Guzman","year":"2000","journal-title":"Oncogene"},{"issue":"5438","key":"pone.0310641.ref031","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1126\/science.286.5438.309","article-title":"The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase","volume":"286","author":"CA Joazeiro","year":"1999","journal-title":"Science"},{"issue":"12","key":"pone.0310641.ref032","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/nrm1762","article-title":"The Cbl interactome and its functions","volume":"6","author":"MHH Schmidt","year":"2005","journal-title":"Nature Reviews Molecular Cell Biology"},{"issue":"1","key":"pone.0310641.ref033","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/jcp.20694","article-title":"The Cbl family proteins: ring leaders in regulation of cell signaling","volume":"209","author":"G Swaminathan","year":"2006","journal-title":"J Cell Physiol"},{"issue":"4","key":"pone.0310641.ref034","first-page":"653","article-title":"The sequences of the human and mouse c-cbl proto-oncogenes show v-cbl was generated by a large truncation encompassing a proline-rich domain and a leucine zipper-like motif","volume":"6","author":"TJ Blake","year":"1991","journal-title":"Oncogene"},{"issue":"19","key":"pone.0310641.ref035","doi-asserted-by":"crossref","first-page":"4515","DOI":"10.1002\/j.1460-2075.1994.tb06773.x","article-title":"Tumour induction by activated abl involves tyrosine phosphorylation of the product of the cbl oncogene","volume":"13","author":"CE Andoniou","year":"1994","journal-title":"EMBO J"},{"issue":"4","key":"pone.0310641.ref036","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0092-8674(00)00057-X","article-title":"Structure of a c-Cbl-UbcH7 complex: RING domain function in ubiquitin-protein ligases","volume":"102","author":"N Zheng","year":"2000","journal-title":"Cell"},{"issue":"2","key":"pone.0310641.ref037","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S1097-2765(01)00183-6","article-title":"RING Finger Mutations that Abolish c-Cbl-Directed Polyubiquitination and Downregulation of the EGF Receptor Are Insufficient for Cell Transformation","volume":"7","author":"CBF Thien","year":"2001","journal-title":"Molecular Cell"},{"issue":"27","key":"pone.0310641.ref038","doi-asserted-by":"crossref","first-page":"28017","DOI":"10.1074\/jbc.M404114200","article-title":"Regulation of ubiquitin protein ligase activity in c-Cbl by phosphorylation-induced conformational change and constitutive activation by tyrosine to glutamate point mutations","volume":"279","author":"CK Kassenbrock","year":"2004","journal-title":"Journal of Biological Chemistry"},{"issue":"12","key":"pone.0310641.ref039","doi-asserted-by":"crossref","first-page":"4789","DOI":"10.1158\/0008-5472.CAN-10-0610","article-title":"Cbl and human myeloid neoplasms: the Cbl oncogene comes of age","volume":"70","author":"SC Kales","year":"2010","journal-title":"Cancer Res"},{"issue":"2","key":"pone.0310641.ref040","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/nsmb.2231","article-title":"Structural basis for autoinhibition and phosphorylation-dependent activation of c-Cbl","volume":"19","author":"H Dou","year":"2012","journal-title":"Nat Struct Mol Biol"},{"issue":"1","key":"pone.0310641.ref041","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12915-016-0298-6","article-title":"Casitas B-lineage lymphoma linker helix mutations found in myeloproliferative neoplasms affect conformation","volume":"14","author":"L Buetow","year":"2016","journal-title":"BMC Biol"},{"issue":"9","key":"pone.0310641.ref042","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1074\/jbc.M116.772723","article-title":"Structural Determinants of the Gain-of-Function Phenotype of Human Leukemia-associated Mutant CBL Oncogene","volume":"292","author":"SA Nadeau","year":"2017","journal-title":"J Biol Chem"},{"issue":"14","key":"pone.0310641.ref043","doi-asserted-by":"crossref","first-page":"3824","DOI":"10.1182\/blood-2011-05-352039","article-title":"Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial","volume":"118","author":"T Braun","year":"2011","journal-title":"Blood"},{"issue":"4","key":"pone.0310641.ref044","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/cncr.22457","article-title":"Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia","volume":"109","author":"A Aribi","year":"2007","journal-title":"Cancer"},{"issue":"4","key":"pone.0310641.ref045","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.leukres.2007.08.004","article-title":"Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML)","volume":"32","author":"PW Wijermans","year":"2008","journal-title":"Leuk Res"},{"issue":"12","key":"pone.0310641.ref046","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1002\/cncr.25759","article-title":"Activity of azacitidine in chronic myelomonocytic leukemia","volume":"117","author":"R Costa","year":"2011","journal-title":"Cancer"},{"issue":"21","key":"pone.0310641.ref047","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1182\/blood.V118.21.1726.1726","article-title":"Prognostic Factors of Response and Survival in CMML Patients Treated with Azacitidine (AZA)","volume":"118","author":"L Ades","year":"2011","journal-title":"Blood"},{"issue":"2","key":"pone.0310641.ref048","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1182\/blood-2017-04-736421","article-title":"How I treat chronic myelomonocytic leukemia","volume":"130","author":"E Solary","year":"2017","journal-title":"Blood"},{"issue":"6","key":"pone.0310641.ref049","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.bbmt.2010.09.018","article-title":"Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities","volume":"17","author":"H Eissa","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"pone.0310641.ref050","article-title":"WHO-Defined Chronic Myelomonocytic Leukemia-2 (CMML-2) Patients Rapidly Progress to AML Suggesting This Entity Represents a Transitory Clinical State","volume":"134","author":"AM Hunter","year":"2019","journal-title":"Blood"},{"issue":"7","key":"pone.0310641.ref051","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1080\/1042819042000207271","article-title":"Risk assessment in chronic myelomonocytic leukemia (CMML)","volume":"45","author":"U Germing","year":"2004","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"pone.0310641.ref052","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1365-2141.2011.08631.x","article-title":"Recent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemia","volume":"153","author":"U Bacher","year":"2011","journal-title":"Br J Haematol"},{"issue":"20","key":"pone.0310641.ref053","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"DA Arber","year":"2016","journal-title":"Blood"},{"issue":"8","key":"pone.0310641.ref054","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1158\/1078-0432.CCR-09-2112","article-title":"RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant","volume":"16","author":"C Ricci","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"1","key":"pone.0310641.ref055","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1038\/s41467-021-23186-w","article-title":"RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis","volume":"12","author":"RM Carr","year":"2021","journal-title":"Nature Communications"},{"issue":"5","key":"pone.0310641.ref056","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1182\/blood.V74.5.1472.1472","article-title":"Interleukin-6 and granulocyte-macrophage colony-stimulating factor are candidate growth factors for chronic myelomonocytic leukemia cells","volume":"74","author":"MP Everson","year":"1989","journal-title":"Blood"},{"issue":"1","key":"pone.0310641.ref057","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/s41375-018-0203-0","article-title":"Heterogeneous expression of cytokines accounts for clinical diversity and refines prognostication in CMML","volume":"33","author":"S Niyongere","year":"2019","journal-title":"Leukemia"},{"issue":"20","key":"pone.0310641.ref058","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1182\/bloodadvances.2019000585","article-title":"The transcriptome of CMML monocytes is highly inflammatory and reflects leukemia-specific and age-related alterations","volume":"3","author":"A Franzini","year":"2019","journal-title":"Blood Adv"},{"issue":"6","key":"pone.0310641.ref059","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1158\/2643-3230.BCD-21-0217","article-title":"Progenitor Hierarchy of Chronic Myelomonocytic Leukemia Identifies Inflammatory Monocytic-Biased Trajectory Linked to Worse Outcomes","volume":"3","author":"MC Ferrall-Fairbanks","year":"2022","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"pone.0310641.ref060","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s40164-022-00284-z","article-title":"Mutational landscape of chronic myelomonocytic leukemia in Chinese patients","volume":"11","author":"Y Nie","year":"2022","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"pone.0310641.ref061","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s12185-021-03210-x","article-title":"Mutational landscape of chronic myelomonocytic leukemia and its potential clinical significance","volume":"115","author":"W Han","year":"2022","journal-title":"International Journal of Hematology"},{"issue":"1","key":"pone.0310641.ref062","doi-asserted-by":"crossref","first-page":"7244","DOI":"10.1038\/s41467-021-27472-5","article-title":"Clonal architecture predicts clinical outcomes and drug sensitivity in acute myeloid leukemia","volume":"12","author":"BA Benard","year":"2021","journal-title":"Nature Communications"},{"issue":"7569","key":"pone.0310641.ref063","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/nature15252","article-title":"Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6","volume":"525","author":"Q Zhang","year":"2015","journal-title":"Nature"},{"issue":"6","key":"pone.0310641.ref064","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.stem.2018.10.013","article-title":"Inhibition of Inflammatory Signaling in Tet2 Mutant Preleukemic Cells Mitigates Stress-Induced Abnormalities and Clonal Hematopoiesis","volume":"23","author":"Z Cai","year":"2018","journal-title":"Cell Stem Cell"},{"issue":"8","key":"pone.0310641.ref065","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1158\/2159-8290.CD-22-1396","article-title":"Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia","volume":"13","author":"WL Kan","year":"2023","journal-title":"Cancer Discov"},{"issue":"31","key":"pone.0310641.ref066","doi-asserted-by":"crossref","first-page":"23687","DOI":"10.1074\/jbc.M109.091157","article-title":"The N terminus of Cbl-c regulates ubiquitin ligase activity by modulating affinity for the ubiquitin-conjugating enzyme","volume":"285","author":"PE Ryan","year":"2010","journal-title":"J Biol Chem"},{"issue":"6","key":"pone.0310641.ref067","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1097-2765(00)80231-2","article-title":"Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl\/Sli-1","volume":"4","author":"G Levkowitz","year":"1999","journal-title":"Mol Cell"},{"issue":"1","key":"pone.0310641.ref068","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1038\/s42003-023-05655-8","article-title":"The co-crystal structure of Cbl-b and a small-molecule inhibitor reveals the mechanism of Cbl-b inhibition","volume":"6","author":"SW Kimani","year":"2023","journal-title":"Communications Biology"},{"issue":"3","key":"pone.0310641.ref069","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1182\/blood-2007-01-066076","article-title":"Flt3-dependent transformation by inactivating c-Cbl mutations in AML","volume":"110","author":"B Sargin","year":"2007","journal-title":"Blood"},{"key":"pone.0310641.ref070","doi-asserted-by":"crossref","first-page":"107518","DOI":"10.1016\/j.leukres.2024.107518","article-title":"Phase 1 study of azacitidine in combination with quizartinib in patients with FLT3 or CBL mutated MDS and MDS\/MPN","volume":"142","author":"G Montalban-Bravo","year":"2024","journal-title":"Leuk Res"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0310641","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T17:41:01Z","timestamp":1726767661000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0310641"}},"subtitle":[],"editor":[{"given":"Michael","family":"Massiah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,9,19]]},"references-count":70,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9,19]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0310641","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,19]]}}}